sars cov mpro in 1

MProinhibitor 11b is an inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (MPro; IC50= 0.04 μM in a TR-FRET assay).1It reduces viral yield in the culture supernatant of SARS-CoV-2-infected Vero E6 cells (EC50= 0.72 μM). MProinhibitor 11b also reduces viral RNA copy numbers in the same model when used at concentrations ranging from 1.85 to 50 μM. 1.Dai, W., Zhang, B., Jiang, X.-M., et al.Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseScience368(6497)1331-1335(2020)

SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent, selective, and irreversible inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 value of 116 nM [1].

SARS-CoV-2 MERS Mpro-IN-1 is a potent inhibitor of the main proteases in SARS-CoV-2 and MERS, with IC50 values of 0.10 and 0.06 µM, respectively.

SARS-CoV-2 Mpro-IN-9 (compound c7), a nonpeptidic, noncovalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibits potent inhibitory action (IC50 = 0.085 μM) and improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. It effectively suppresses viral replication in SARS-CoV-2-infected Vero E6 cells (EC50 = 1.10 μM) and demonstrates low cytotoxicity (CC50 > 50 μM) [1].

SARS-CoV-2-IN-1 is a potent inhibitor of Mpro [SARS-CoV-2 Mpro, SARS-CoV Mpro, and MERS-CoV Mpro] with IC50 values of 0.67, 0.90, and 0.58 μM, respectively.

SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 MPro with an IC50 value of 230 nM. In vitro, it also inhibits the replication of various SARS-CoV-2 variants.

SARS-CoV-2 Mpro-IN-37 (compound 8r) is an inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 value of 0.0199 μM. It exhibits IC50 values of 0.00945 μM against SARS-CoV-1 Mpro and 0.111 μM against MERS-CoV Mpro. SARS-CoV-2 Mpro-IN-37 demonstrates potent antiviral activity in the nanomolar range without showing cytotoxicity.

SARS-CoV-2 Mpro ligand 1 is a ligand for the target protein PROTAC. It is utilized in the synthesis of [BP-198].

SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor targeting COX-2 and SARS-CoV-2 Mpro, with respective IC50 values of 9.66 μM and 13.24 μM. It also demonstrates inhibitory activity against COX-1 (IC50: 46.11 μM). This compound significantly suppresses the expression of inflammation-related cytokines such as TNF-α, IL-6, and IL-1β, exhibiting anti-inflammatory properties. By selectively inhibiting COX-2 and SARS-CoV-2 Mpro, SARS-CoV-2 Mpro-IN-41 exerts both anti-inflammatory and antiviral effects, making it a potential candidate for research in inflammation and COVID-19 treatment.

SARS-CoV-2 Mpro-IN-43 (Compound 1) is an inhibitor of the coronavirus main protease (Mpro) with an IC50 of 72 μM. It exerts its antiviral effects by interacting non-covalently with the key residues at the Mpro active site. This compound exhibits moderate to low cytotoxicity with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 is applicable for SARS-CoV-2 research.

Mpro inhibitor N3 hemihydrate is a potent antagonist of the SARS-CoV-2 main protease (Mpro), with an EC50 of 16.77 μM against SARS-CoV-2. It specifically inhibits Mpro in various coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E (IC50 4.0 μM), FIPV (IC50 8.8 μM), and MHV-A59 (IC50 2.7 μM) [1][2].

Mpro PLpro-IN-1 (Compound 29) is a dual-acting inhibitor of SARS-CoV-2 protease, displaying micromolar inhibition of Mpro (IC50: 1.72 μM) and submicromolar inhibition of PLpro (IC50: 0.67 μM).

SP inhibitor 1 is an inhibitor of SARS-CoV-2 replication at non-toxic concentrations (0.3250<5.98 μM) in vitro. SP inhibitor 1 is a selective inhibitor of SARS-CoV-2 stinger protein (SP), acting on SP protein (IC50: 3.26 μM), Mpro protein (IC50>25 μM) and PLpro protein (IC50>25 μM), and has cellular antiviral effects. and PLpro protein (IC50>25 μM), and has cellular antiviral effects.

(±)-Alliin is a derivative of cysteine and a natural component of fresh garlic that can be converted into allicin by alliinase.

TKB245 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), effectively inhibiting viral replication in VeroE6 cells [1].

SARS-CoV-2-IN-50 (Compound X77C) is a potent inhibitor of the SARS-CoV-2 main protease (M^pro), demonstrating high affinity for the enzyme's catalytic site [1].

SARS-CoV-2 Mpro-IN-7 (compound 6g) effectively inhibits the SARS-CoV-2 main protease (Mpro) with an IC50 value of 8.8 μM and exhibits a cytotoxic concentration (CC50) of 10 μM [1].

SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral agent effective against SARS-CoV-2 [1].

SARS-CoV-2 Mpro-IN-10 (27h) is a potent inhibitor of the Mpro enzyme, with IC50 and EC50 values of 10.9 nM and 43.6 nM, respectively. It is used in research on the SARS-CoV-2 virus [1].

MPI60 is a potent inhibitor of SARS-CoV-2 main protease (M^pro) exhibiting high antiviral efficacy, low cellular cytotoxicity, and considerable in vitro metabolic stability, making it suitable for SARS-CoV-2 research [1].

SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent targeting SARS-CoV-2, demonstrating an EC50 of 18 μM and specifically inhibiting the SARS-CoV-2 main protease (Mpro) with an IC50 of 0.35 μM [1].

Hydroxyaloin A (10-10-Hydroxyaloin A) is a potent inhibitor of SARS-CoV-2, demonstrating significant efficacy in binding to the active site of the SARS-CoV-2 main protease (M^pro) [1].

SARS-CoV-2-IN-59 (compound E07), an imidazoline derivative, is a non-peptide small molecule that inhibits SARS-CoV-2 by targeting its main protease (Mpro) and exhibits robust binding with Mpro residues (Met 165, Gln 166, Met 165, His 41, Gln 189) [1].

SARS-CoV-2-IN-69 (Compound 7E) is a potent, non-covalent inhibitor of the SARS-CoV-2 main protease (M^pro) with an EC50 of 7.4 μM and also inhibits the papain-like protease (PL^pro) [1].